华为IPD流程管理体系：L1至L5最佳实践揭秘（PPT） - 搜狐
2024年6月24日 · Level 1：流程分类，支撑公司战略和业务目标。 Level 2：流程组，细化流程，聚焦战略执行。 Level 3：具体流程，进一步明确业务活动。 Level 4：子流程，细分流程， …
Deferiprone (GPO-L-ONE (®) ) monotherapy reduces iron
Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose …
三豪：华为流程化组织建设：组织与流程，应像眼镜蛇一样 - 知乎
华为还为每一个l1流程任命全球流程责任人（gpo），基于公司发展战略，gpo负责流程和流程管理团队建设、打造流程 执行力文化 ，以及流程的推行和改善等，确保流程高效运作。
Effectiveness of Deferiprone (GPO-L-ONE®) Chelation Therapy in …
Conclusion: Deferiprone (GPO-L-ONE ®) is an effective oral iron-chelating agent for treatment of iron overload in thalassemia. Close safety monitoring is required. Key Words: Thalassemia, …
GPO-L-One is used to treat iron overload caused by frequent blood transfusions in patients with thalassaemia major (a type of anaemia). How GPO-L-One works . GPO-L-One contains the …
Deferiprone (GPO-L-ONE - Wiley Online Library
2013年1月6日 · In this study, deferiprone (GPO-L-ONE ®) was further evaluated as a monotherapy for its efficacy on body iron reduction and safety profile in transfusion dependent …
Safety and Effectiveness of Oral Deferiprone (GPO-L-ONE®) in …
2018年1月6日 · Viprakrasit V, Nuchprayoon I, Chuansumrit A, Torcharus K, Pongtanakul B, Laothamatas J, et al. Deferiprone (GPO-L-ONE®) monotherapy reduces iron overload in …
The oral chelator deferiprone (GPO-L-ONE®) was approved by the Thai Food and Drug Administration (FDA) in 2008 and began being administered at the provincial hospital in …
A liquid formulation of deferiprone (GPO-L-ONE ) in a daily dose of 50 to 100 mg/kg divided in 3 doses, was given to transfusion-dependent thalassemia children
2022年12月1日 · This study aims to assess deferiprone (GPO-L-ONE®) outcomes in thalassemia children patients who iron overload. A retro-spective-descriptive study was conducted in …